DaVita Inc. (NYSE:DVA) Stake Trimmed by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lessened its stake in DaVita Inc. (NYSE:DVA - Free Report) by 50.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 24,732 shares of the company's stock after selling 25,364 shares during the quarter. Assenagon Asset Management S.A.'s holdings in DaVita were worth $4,054,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DVA. Harvard Management Co. Inc. acquired a new position in shares of DaVita in the 2nd quarter valued at approximately $55,115,000. Lazard Asset Management LLC raised its position in shares of DaVita by 147.3% in the 1st quarter. Lazard Asset Management LLC now owns 256,872 shares of the company's stock valued at $35,460,000 after purchasing an additional 153,008 shares in the last quarter. Jupiter Asset Management Ltd. raised its position in shares of DaVita by 146.7% in the 1st quarter. Jupiter Asset Management Ltd. now owns 187,177 shares of the company's stock valued at $25,840,000 after purchasing an additional 111,311 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of DaVita in the 2nd quarter valued at approximately $9,615,000. Finally, International Assets Investment Management LLC acquired a new position in shares of DaVita in the 3rd quarter valued at approximately $10,346,000. Hedge funds and other institutional investors own 90.12% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Truist Financial upped their price target on DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a research report on Monday, October 7th. TD Cowen raised their price objective on DaVita from $139.00 to $150.00 and gave the stock a "hold" rating in a research note on Wednesday, July 24th. UBS Group raised their price objective on DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a research note on Thursday, August 8th. Finally, Bank of America raised their price objective on DaVita from $139.00 to $145.00 and gave the stock an "underperform" rating in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $159.00.

Insider Buying and Selling

In related news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the transaction, the chief executive officer now directly owns 837,835 shares of the company's stock, valued at $138,284,666.75. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the transaction, the chief executive officer now directly owns 837,835 shares of the company's stock, valued at $138,284,666.75. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Joel Ackerman sold 64,029 shares of DaVita stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total value of $9,928,336.74. Following the completion of the transaction, the chief financial officer now directly owns 111,481 shares in the company, valued at $17,286,243.86. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 173,482 shares of company stock valued at $27,387,069 over the last three months. Company insiders own 2.00% of the company's stock.

DaVita Stock Performance

Shares of DVA traded down $17.77 during trading hours on Wednesday, reaching $140.54. 1,894,688 shares of the company's stock traded hands, compared to its average volume of 810,526. The firm has a market capitalization of $11.79 billion, a price-to-earnings ratio of 15.67, a P/E/G ratio of 0.90 and a beta of 0.87. The company has a debt-to-equity ratio of 9.94, a current ratio of 1.16 and a quick ratio of 1.12. DaVita Inc. has a twelve month low of $76.17 and a twelve month high of $168.50. The business's fifty day simple moving average is $158.40 and its two-hundred day simple moving average is $146.05.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). The business had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. DaVita's revenue for the quarter was up 4.6% on a year-over-year basis. During the same period last year, the business posted $2.85 earnings per share. Analysts predict that DaVita Inc. will post 9.99 earnings per share for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.